Atumelnant

Jefferies upgraded Crinetics Pharmaceuticals to "Buy," citing investor concerns about Phase 2 data for atumelnant creating a buying opportunity.

Crinetics Pharmaceuticals' atumelnant significantly reduced key biomarkers in adults with congenital adrenal hyperplasia (CAH) in a Phase 2 trial.

Crinetics Pharmaceuticals' atumelnant demonstrated significant A4 reductions in a Phase 2 trial, positioning it favorably against existing treatments for congenital adrenal hyperplasia (CAH).

Crinetics Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for paltusotine, a novel oral somatostatin receptor type 2 agonist, for treating acromegaly.

The FDA has accepted two New Drug Applications for Neurocrine Biosciences' crinecerfont, granting Priority Review for treating classic congenital adrenal hyperplasia (CAH).